StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
FDBK.L$7.70-4.94%
Fair $7.70+0.0%

FDBK.L

Feedback plc

Healthcare / Health Information ServicesLSE

$7.70

-0.40 (-4.94%)

Fairly Valued+0.0%Fair Value $7.70Fund rank 27/100 · Data gapFallback financials|
SA 10/F
F-Score: 1/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-3.5M · quality 55.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 36/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

10/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.2%, below the 5% threshold
Thesis & Journal · FDBK.LLocal privado en este navegador · Feedback plc
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-118.7%

↓

Gross Margin

87.9%

↑

Debt/Equity

N/A

•
52-Week Range$8
$8$15

TradingView lightweight chart

FDBK.L price, volumen y niveles de valoración

Último $8.100Periodo -100.0%
Fair value: $7.700

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+14.6%

FCF CAGR

—

FCF margin

-412.7%

FCF / Net income

0.50x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $885623.0 · net income $-7.3M · FCF $-3.7M

2022-FY → 2025-FY

Gross margin

87.9%+4.8% pts

Operating margin

-475.4%-48.4% pts

Net margin

-826.2%-466.3% pts

FCF margin

-412.7%-338.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$885623.00$885623.00$1.2M$1.0M$588576.00
Net Income$-7.3M$-7.3M$-3.3M$-2.9M$-2.1M
EBITDA$-3.1M$-3.1M$-2.7M$-2.6M$-2.0M
EPS-0.26-0.26-0.25-0.22-0.22
Gross Margin87.9%87.9%93.3%91.8%83.1%
Operating Margin-475.4%-475.4%-312.3%-333.9%-427.0%
Net Margin-826.2%-826.2%-279.2%-284.7%-360.0%
Balance Sheet
Current Ratio10.3410.34———
Cash Flow
Free Cash Flow$-3.7M$-3.7M$-3.5M$-3.0M$-434519.00
Returns
ROE-118.7%-118.7%-43.1%-26.8%-15.5%
Valuation
P/B35.8535.85116.87141.0992.03
Growth & Yield
Revenue Growth-25.0%-25.0%15.3%74.1%—
EPS Growth-3.1%-3.1%-13.1%0.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -46.9%

Total return

-46.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.25 → -0.26

Residual

-46.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-46.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.